Zobrazeno 1 - 10
of 275
pro vyhledávání: '"Jacques, Bonneterre"'
Autor:
Iain R. Macpherson, Pavlina Spiliopoulou, Saeed Rafii, Matilde Saggese, Richard D. Baird, Javier Garcia-Corbacho, Antoine Italiano, Jacques Bonneterre, Mario Campone, Nicola Cresti, John Posner, Yousuke Takeda, Akinori Arimura, James Spicer
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2019)
Abstract Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4. This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily oral epertinib combined with trastuzumab (arm A), with
Externí odkaz:
https://doaj.org/article/1caffbf612894f738efaee3a4d3d13dc
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Multigene signatures refine the risk of recurrence and guide adjuvant chemotherapy decision in luminal breast cancers. The decision to perform the assay is highly variable among oncologists. In order to guide the appropriate clinical grou
Externí odkaz:
https://doaj.org/article/98814cab7d904edfb502a2b33a794aea
Autor:
Paul H Cottu, Jacques Bonneterre, Andrea Varga, Mario Campone, Alexandra Leary, Anne Floquet, Dominique Berton-Rigaud, Marie-Paule Sablin, Anne Lesoin, Keyvan Rezai, François M Lokiec, Catherine Lhomme, Jacques Bosq, Alice S Bexon, Erard M Gilles, Stefan Proniuk, Veronique Dieras, David M Jackson, Alexander Zukiwski, Antoine Italiano
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204973 (2018)
INTRODUCTION:Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with bre
Externí odkaz:
https://doaj.org/article/02cc52265fd94e9ab36980e19f1d5162
Autor:
Emilie Le Rhun, Sophie Taillibert, Thomas Boulanger, Fahed Zairi, Jacques Bonneterre, Marc C. Chamberlain
Publikováno v:
Case Reports in Oncology, Vol 8, Iss 1, Pp 72-77 (2015)
Background: Survival of patients with leptomeningeal metastases (LM) and impaired functional status is limited to several months, and rarely does neurological function improve with treatment. Case Report: A 34-year-old female with hormone-negative an
Externí odkaz:
https://doaj.org/article/284b4ef701e04ab5987fd301fba0184c
Autor:
Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, Litaty Mbatchi, André van Kuilenburg, Christine Bobin-Dubigeon, Fabienne Thomas, Etienne Chatelut, Jean-Louis Merlin, Frédéric Pinguet, Christophe Ferrand, Judith Meijer, Alexandre Evrard, Laurence Llorca, Gilles Romieu, Philippe Follana, Thomas Bachelot, Loic Chaigneau, Xavier Pivot, Véronique Dieras, Rémy Largillier, Mireille Mousseau, Anthony Goncalves, Henri Roché, Jacques Bonneterre, Véronique Servent, Nadine Dohollou, Yann Château, Emmanuel Chamorey, Jean-Pierre Desvignes, David Salgado, Jean-Marc Ferrero, Gérard Milano
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0175998 (2017)
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The g
Externí odkaz:
https://doaj.org/article/e851b305e66844848f3f60697e611308
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 555-559 (2014)
Breast tumors overexpressing Her2 (15% of breast cancers) are particularly at risk for central nervous system parenchymal metastases. Whole-brain irradiation (WBI) is the standard of care of brain metastases (BM), and secondarily, systemic treatment
Externí odkaz:
https://doaj.org/article/702f53b84f6c440ea7dfb89e53d6afe8
Autor:
Soulaimane Aboulouard, Jacques Bonneterre, Nawale Hajjaji, Yves Marie Robin, Delphine Bertin, Isabelle Fournier, Michel Salzet
Publikováno v:
Cancer Research. 80:P4-07
Background Estimating the risk of relapse in early luminal breast cancers is paramount to determine the therapeutic strategy. Genomic signatures have come along clinical/pathological factors to refine this estimation. However, cases of tumors with di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20c27d2621c785c3f05323581b836d0e
https://doi.org/10.1158/1538-7445.sabcs19-p4-07-08
https://doi.org/10.1158/1538-7445.sabcs19-p4-07-08
Autor:
Rose-Marie Javier, Béatrice Bouvard, Christophe Hennequin, Didier Mayeur, Jean-Michel Hannoun-Levi, Eric Lespessailles, Florence Trémollières, Cyrille B. Confavreux, Catherine Cormier, Bernard Cortet, Françoise Debiais, Pierre Kerbrat, A. Lesur, Julien Paccou, Jacques Bonneterre, Marie-Hélène Vieillard, Karine Briot
Publikováno v:
Joint Bone Spine
Joint Bone Spine, Elsevier Masson, 2019, 86 (5), pp.542-553. ⟨10.1016/j.jbspin.2019.07.005⟩
Joint Bone Spine, Elsevier Masson, 2019, 86 (5), pp.542-553. ⟨10.1016/j.jbspin.2019.07.005⟩
Standard adjuvant therapies for breast cancer such as chemotherapy or aromatase inhibitor and LH-RH agonist hormone therapy are associated with significant survival gains but also induce bone loss by aggravating the estrogen deprivation. The bone los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55823c2a1c1ea9670405bde61a7b7a29
https://doi.org/10.1016/j.jbspin.2019.07.005
https://doi.org/10.1016/j.jbspin.2019.07.005
Autor:
Eric Lespessailles, Julien Paccou, Rose-Marie Javier, Didier Mayeur, Catherine Cormier, Bernard Cortet, Cyrille B. Confavreux, Karine Briot, A. Lesur, Jean-Michel Hannoun-Levi, Françoise Debiais, Béatrice Bouvard, Christophe Hennequin, Pierre Kerbrat, Marie-Hélène Vieillard, Florence Trémollières, Jacques Bonneterre
Publikováno v:
Revue du Rhumatisme
Revue du Rhumatisme, Elsevier, 2019, 86, pp.426-437. ⟨10.1016/j.rhum.2019.05.005⟩
Revue du Rhumatisme, Elsevier, 2019, 86, pp.426-437. ⟨10.1016/j.rhum.2019.05.005⟩
Resume Les traitements adjuvants standards du cancer du sein comme la chimiotherapie et les hormonotherapies par inhibiteurs de l’aromatase et/ou analogues de la LH-RH sont associes a un gain significatif de survie des patientes mais sont responsab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33141b61e0729802f92ab4be793c5d04
https://doi.org/10.1016/j.rhum.2019.05.005
https://doi.org/10.1016/j.rhum.2019.05.005
Autor:
Rachel Wuerstlein, Margarita Donica, Antonio Anton, Jacques Bonneterre, Suzette Delaloge, N Quenel-Tueux, Natsumi Irahara, Nicolas Lindegger, Sabine C. Linn, Carlos H. Barrios, Paul Anthony Ellis, Filippo Montemurro
Publikováno v:
European Journal of Cancer. 109:92-102
Background Many patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) are candidates for trastuzumab emtansine (T-DM1) treatment sometime in their disease history. KAMILLA evaluated safety of T-DM1 in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b412d579bec3c6f6c31d030b4d2e2f91
https://doi.org/10.1016/j.ejca.2018.12.022
https://doi.org/10.1016/j.ejca.2018.12.022